Having said that, a individual Evaluation from Delveinsight indicates that whilst Epidyolex is set to continue dominating the market and remaining a critical earner for Jazz while in the near long term, a rising range of practical choice therapies in the unusual epilepsies, particularly from bexicaserin and zorevunersen, which are now advancing by